immunity News and Research

RSS

Less severe clinical consequences of infection with SARS-CoV-2 Omicron variant

New evidence implies that the Omicron variant may cause a less severe and/or faster recovery from clinical COVID-19 disease.

31 Dec 2021

Omicron infection induces cross-reactive immune responses

New research revealed that vaccine-breakthrough infections might elicit cross-reactive bNAbs against all variants of concern.

31 Dec 2021

SARS-CoV-2 omicron variant may be less severe than the delta variant

A new study reveals that omicron infections in South Africa are associated with lower rates of hospital admissions and lower disease severity compared to beta and delta infections.

31 Dec 2021

A reliable assessment of COVID-19 vaccine protection duration

Researchers from the University of North Carolina, University of Washington, and the US Food and Drug Administration propose fitting a Cox model with two time indexes, the event times measured from the start of the study in calendar time and the log hazard for the vaccine effect.

30 Dec 2021

How much do mutations reduce vaccine effectiveness in the Omicron variant?

In new research, scientists from Adaptive Biotechnologies have been investigating the impact of spike protein mutations on vaccine efficiency for the Omicron variant. The study is currently available on the medRxiv* preprint server while awaiting peer review.

30 Dec 2021

Vaccine-induced T-cells vs. Omicron well preserved compared with all variants

A team of international scientists has recently revealed that T cell responses induced by coronavirus disease 2019 (COVID-19) vaccines are able to cross-recognize different variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study is currently available on the bioRxiv* preprint server.

30 Dec 2021

SARS-CoV-2 infection and immunity in pregnancy and fetal development

A review conducted by a team of researchers from the Icahn School of Medicine at Mount Sinai, the University of Colorado, and Active Motif, Incorporated compiles information on SARS-CoV-2 virology, in utero transmission from infected pregnant mothers to fetuses, new findings on possible methods of SARS-CoV-2 cellular trafficking through exosomes, and the transcriptomic effects of SARS-CoV-2 infection, in order to inform future studies aimed at a better understanding of COVID-19 and the development of therapeutic solutions against SARS-CoV-2.

30 Dec 2021

Antibody neutralization of SARS-CoV-2 Omicron variant via BNT162b2 vaccine booster dose

New study findings highlight the need for a rapid booster vaccine campaign to prevent COVID-19 caused by the Omicron variant since the neutralization of Omicron by the two-dose BNT162b2 vaccine is not effective in controlling the spread of the infection.

30 Dec 2021

Study shows varying population immunity against SARS-CoV-2

Researchers analyzed the combined distribution of COVID-19 vaccination and prior SARS-CoV-2 infection in each state and county in the US since the beginning of the COVID-19 epidemic to estimate the changes in the population immunity during this period.

30 Dec 2021

Recombinant adjuvanted zoster vaccination associated with lower risk of COVID-19 diagnosis and hospitalization

A new study suggests that RZV may elicit durable innate immune responses in the elderly conferring heterologous protection against COVID-19. .

30 Dec 2021

Study explores relative reproduction of the SARS-CoV-2 omicron variant in South Africa

A new study, focused on the SARS-CoV-2 Omicron variant, presented a modeling result from an analysis of genome surveillance data in Gauteng province, South Africa, using an existing estimation technique.

30 Dec 2021

Orphanhood decreases with the availability of antiretroviral therapy and male circumcision

Researchers at Columbia University Mailman School of Public Health found marked decreases in orphanhood particularly double orphanhood, among adolescents in Rakai, Uganda, corresponding with the availability of antiretroviral therapy (ART) beginning in 2004 and of male medical circumcision in 2007.

30 Dec 2021

Once-a-day antiretroviral medicine for children proven to be more effective at suppressing HIV

A once-a-day antiretroviral medicine that is low-cost and easy for children to take is also more effective at suppressing HIV than standard treatments, according to a global trial led by researchers at UCL.

30 Dec 2021

At least 3 exposures to vaccine or virus needed for minimum protection against SARS-CoV-2 Omicron

Researchers determine the serum neutralizing and binding activity against the SARS-CoV-2 Omicron variant in individuals with different levels of immunity.

29 Dec 2021

BNT162b2 booster restores protection following waning of the 2-dose vaccine

Researchers assess the real-world effectiveness of a third booster dose of the Pfizer-BioNTech BNT162b2 vaccine against the initial two-dose regimen.

29 Dec 2021

Researchers suggest hybrid convalescent plasma therapy neutralizes the omicron variant

New research suggests convalescent plasma from unvaccinated donors is not effective against the Omicron variant, however, “hybrid” convalescent plasma from donors who recovered from COVID-19 infection and are vaccinated provides considerable antibody protection.

29 Dec 2021

Animal study suggests Omicron is less infectious than previous SARS-CoV-2 strains

A new study suggests the Omicron (B.1.1.529) variant is not as infectious as scientists initially assumed.

29 Dec 2021

Study shows fully vaccinated individuals preserve cross-neutralizing memory B-cells against SARS-CoV-2 Omicron variant

A new study found increases in resting memory B cell subsets showed strong cross-reactivity against several variants, including Omicron.

29 Dec 2021

Impact of an omicron outbreak at a private gathering in the Faroe Islands

New findings suggest that the Omicron variant has potent immune-escape capabilities, putting even newly boosted patients at risk of infection.

29 Dec 2021

3-dose vaccines deemed ultrapotent against diverse and highly transmissible SARS-CoV-2 Omicron and other variants

A new study found that the presence of a subset of antibodies with broad neutralizing activities against all circulating variants of concern in the three-dose vaccines' memory B-derived antibody repertoire suggests that the Omicron/future variants infection may elicit selective and rapid recall of humoral responses, conferring secondary protection directed by memory etched in the immune system.

29 Dec 2021

immunity News and Research

Less severe clinical consequences of infection with SARS-CoV-2 Omicron variant

Omicron infection induces cross-reactive immune responses

SARS-CoV-2 omicron variant may be less severe than the delta variant

A reliable assessment of COVID-19 vaccine protection duration

How much do mutations reduce vaccine effectiveness in the Omicron variant?

Vaccine-induced T-cells vs. Omicron well preserved compared with all variants

SARS-CoV-2 infection and immunity in pregnancy and fetal development

Antibody neutralization of SARS-CoV-2 Omicron variant via BNT162b2 vaccine booster dose

Study shows varying population immunity against SARS-CoV-2

Recombinant adjuvanted zoster vaccination associated with lower risk of COVID-19 diagnosis and hospitalization

Study explores relative reproduction of the SARS-CoV-2 omicron variant in South Africa

Orphanhood decreases with the availability of antiretroviral therapy and male circumcision

Once-a-day antiretroviral medicine for children proven to be more effective at suppressing HIV

At least 3 exposures to vaccine or virus needed for minimum protection against SARS-CoV-2 Omicron

BNT162b2 booster restores protection following waning of the 2-dose vaccine

Researchers suggest hybrid convalescent plasma therapy neutralizes the omicron variant

Animal study suggests Omicron is less infectious than previous SARS-CoV-2 strains

Study shows fully vaccinated individuals preserve cross-neutralizing memory B-cells against SARS-CoV-2 Omicron variant

Impact of an omicron outbreak at a private gathering in the Faroe Islands

3-dose vaccines deemed ultrapotent against diverse and highly transmissible SARS-CoV-2 Omicron and other variants

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News